Stockscreener 앱 받기
19.75
3.94%
-0.81
전일 마감가:
$20.56
열려 있는:
$19.97
하루 거래량:
319.21K
Relative Volume:
0.02
시가총액:
$1.04B
수익:
$29.71M
순이익/손실:
$-69.15M
주가수익비율:
-20.36
EPS:
-0.97
순현금흐름:
$-52.28M
1주 성능:
-11.83%
1개월 성능:
+52,991%
6개월 성능:
+52,991%
1년 성능:
+52,991%
1일 변동 폭
$19.13
$20.08
1주일 범위
$19.02
$24.50
52주 변동 폭
$19.02
$29.16
Aktis Oncology Inc Stock (AKTS) Company Profile
AKTS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AKTS
Aktis Oncology Inc
|
19.75 | 1.08B | 29.71M | -69.15M | -52.28M | -0.97 |
|
CSCO
Cisco Systems Inc
|
75.19 | 297.32B | 57.70B | 10.60B | 12.73B | 2.6521 |
|
MSI
Motorola Solutions Inc
|
400.61 | 65.70B | 11.31B | 2.12B | 2.41B | 12.46 |
|
NOK
Nokia Corp Adr
|
6.55 | 36.66B | 21.81B | 920.12M | 1.46B | 0.175 |
|
CIEN
Ciena Corp
|
243.42 | 34.34B | 4.77B | 123.34M | 665.28M | 0.8495 |
|
UI
Ubiquiti Inc
|
550.39 | 33.49B | 2.76B | 791.81M | 589.67M | 13.08 |
Aktis Oncology Inc Stock (AKTS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-01-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-09-06 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2023-01-24 | 개시 | B. Riley Securities | Buy |
| 2021-02-02 | 재확인 | Craig Hallum | Buy |
| 2021-01-15 | 재확인 | Craig Hallum | Buy |
| 2019-09-18 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2019-07-10 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2019-05-13 | 재확인 | Craig Hallum | Buy |
| 2019-02-05 | 재확인 | Craig Hallum | Buy |
| 2019-02-05 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2018-12-18 | 개시 | Craig Hallum | Buy |
| 2018-11-30 | 개시 | Lake Street | Buy |
| 2018-06-22 | 개시 | Loop Capital | Buy |
| 2018-02-09 | 개시 | Drexel Hamilton | Buy |
모두보기
Aktis Oncology Inc 주식(AKTS)의 최신 뉴스
United StatesGoodwin Advises Aktis Oncology In Closing Of $365.4 Million Upsized Initial Public Offering And Full Exercise Of Underwriters’ Option To Purchase Additional Shares - Mondaq
Wednesday Insider Activity: Mitsui’s $55.6M Berkley Buy Leads the Pack - Investing.com Canada
Biotech Venture Limped Through 2025. A Brighter 2026 Beckons. - The Wall Street Journal
Insiders Make Bold Move as Key Players Double Down on Aktis Oncology - TipRanks
Aktis Oncology director Foley buys $4.19 million in shares - Investing.com
Aktis Oncology: Mpm funds buy shares worth $20m By Investing.com - Investing.com Nigeria
Aktis Oncology: Mpm funds buy shares worth $20m - Investing.com
Aktis Oncology (AKTS) sees $20 million purchase by 10% owner By Investing.com - Investing.com Nigeria
Aktis Oncology (AKTS) sees $20 million purchase by 10% owner - Investing.com India
Hedge Fund and Insider Trading News: Crispin Odey, Bill Ackman, Warren Buffett, Ray Dalio, ExodusPoint Capital, Saba Capital Management, Aktis Oncology Inc (AKTS), Warrior Met Coal Inc (HCC), and More - Insider Monkey
A Fresh IPO That Long-Term Investors Shouldn’t Ignore - Investing.com
A Fresh IPO That Long-Term Investors Shouldn't Ignore - Finviz
A Fresh IPO That Long-Term Investors Shouldn’t Ignore - Yahoo Finance
Assessing Aktis Oncology (AKTS) Valuation After Recent Share Price Movement And Ongoing Losses - simplywall.st
Insider Stock Purchases: January 13, 2026 - Quiver Quantitative
Aktis Oncology Stock (AKTS) Opinions on Upsized IPO - Quiver Quantitative
Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
New cancer radiopharma player Aktis Oncology raises $365M IPO - Stock Titan
RTW Biotech Opp.Aktis announces $318 million IPO - Research Tree
Inside Biotech: Eikon Therapeutics joins IPO queue with late-stage oncology focus - Proactive financial news
Major Insider Moves Signal Growing Confidence in Aktis Oncology - TipRanks
Aktis Oncology director Nodelman buys $40 million in shares - Investing.com
Aktis Oncology director Nodelman buys $40 million in shares By Investing.com - Investing.com India
There's a biotech boom in dealmaking - Axios
Eli Lilly-backed Aktis Oncology gets $317.7 million in US IPO - MSN
Opening Day: Aktis Oncology raises $318M in 2026’s first biotech IPO - TipRanks
Aktis Has First Biotech IPO of 2026, Raising $318M to Expand the Reach of Radiopharmaceuticals - Dealbreaker
Aiming to become ‘generational leader’, Eikon goes public - The Pharma Letter
Veradermics, Eikon Eye Public Market Debut as IPO Tap Opens - BioSpace
Aktis Oncology’s IPO tests reopening of biotech markets - The Pharma Letter
Inside Biotech: Aktis Oncology’s IPO signals early momentum for 2026 biotech markets - Proactive financial news
Biotech Market Awakens as Aktis Oncology Enters Public Arena - Kalkine Media
Aktis Oncology Prices Upsized IPO at $1 Billion Market Cap, Closes +24% - Intellectia AI
Aktis Oncology targets up to $945 million valuation in upsized US IPO - MSN
Aktis Oncology IPO Launches Amid $2 Billion Raised by Seven Biotech Follow-On Offerings - geneonline.com
U.S. IPO Weekly Recap: Aktis Oncology Leads As First Sizable 2026 IPO - Seeking Alpha
Private biotechs draw $2B in huge fundraising week: Venture Report - BioCentury
Warm welcome for Aktis could open up IPO queue: Public Equity Report - BioCentury
Aktis Oncology, Inc. (AKTS): Radiopharmaceutical Bio IPO Delivers Breakout to Open 2026 Calendar - Smartkarma
Aktis Oncology Prices Upsized IPO at $318 Million, Targets Solid Tumors - Intellectia AI
Eikon looks to ride wave of IPO momentum - FirstWord
Aktis Oncology, Clinical-Stage Radiopharmaceutical Oncology, Files for Nasdaq Global Select Market IPO - TradingView — Track All Markets
Finance Watch: Aktis Tests 2026 IPO Waters With Year’s First Offering, Raising $318m - Citeline News & Insights
Eli Lilly-Backed Aktis Jumps 24% After $318 Million US IPO - Bloomberg.com
ICR Healthcare Kicks Off '26 IPO Year - O'Dwyer's PR
Aktis raises $318M in first biopharma IPO of 2026 - BioWorld MedTech
Aktis’ 25% IPO bounce builds hope for 2026’s public offerings - Endpoints News
Aktis Oncology Jumps 27% After $318 Million Upsized IPO - GuruFocus
Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets - Business Wire
Lilly partner Aktis surges on trading debut (AKTS:NASDAQ) - Seeking Alpha
Aktis Oncology shares surge 50% in Nasdaq debut By Investing.com - Investing.com Nigeria
Aktis Oncology Inc (AKTS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Aktis Oncology Inc 주식 (AKTS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| MPM BIOVENTURES 2018, L.P. | 10% Owner |
Jan 12 '26 |
Buy |
18.00 |
1,112,777 |
20,029,986 |
10,260,064 |
| GADICKE ANSBERT | 10% Owner |
Jan 12 '26 |
Buy |
18.00 |
1,112,777 |
20,029,986 |
10,260,064 |
| EcoR1 Capital, LLC | Director |
Jan 12 '26 |
Buy |
18.00 |
2,222,222 |
39,999,996 |
4,348,658 |
| Vida Ventures II, LLC | 10% Owner |
Jan 12 '26 |
Buy |
18.00 |
835,000 |
15,030,000 |
5,671,825 |
| Kim Helen Susan | Director |
Jan 12 '26 |
Buy |
18.00 |
835,000 |
15,030,000 |
5,671,825 |
4.73%
0.92%
자본화:
|
볼륨(24시간):